



TriMark Publications

July 2011
Volume: TMRPET11-0701

POSITRON EMISSION TOMOGRAPHY MARKETS *(SAMPLE COPY, NOT FOR RESALE)*

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1. Overview	12
1.1 Scope of This Report	12
1.2 Methodology	14
1.3 Executive Summary	15
2. PET Technology: An Overview	18
2.1 History and Development of PET	18
2.1.1 Early Beginnings	18
2.1.2 The 1950s: Pioneering Ideas for PET	18
2.1.3 The 1960s and 1970s: The Development of PET	18
2.1.4 The 1980s: PET's Advancement and Performance in Research Sector	19
2.1.5 The 1990s: PET's Progression in the Clinical Sector	20
2.1.5.1 PET Advancements of the 1990s	20
2.1.5.2 PET's Ability to Identify Pathophysiology	20
2.1.5.3 Insurance Coverage for PET	21
2.1.5.4 Availability of FDG	21
2.1.6 The 2000s: PET/CT Scanner	21
2.1.7 The Working of PET	22
2.1.8 Coincidence Detection	23
2.1.9 Coincidence Imaging	24
2.1.10 PET Modes	25
2.1.11 Obstacles to Widespread Use of PET	25
2.1.12 Dedicated PET Equipment	26
2.2 PET's Comparison with Other Conventional Imaging Procedures	27
2.3 Trends in PET Instrumentation	29
2.3.1 Advances in PET/CT Imaging	29
2.3.2 Promise of PET/MR Imaging	30
2.4 Cost Considerations in PET Scanners	32
2.5 Economics of Hybrid Systems	32
2.5.1 Hybrid Optimization	33
2.5.2 Image Quality and Hybrids	33
3. PET Applications: An Overview	34
3.1 Applications of PET and PET/CT in Oncology	34
3.1.1 PET/CT's Growth in Clinical Oncology in the U.S. and Europe	35
3.1.2 Cancer: Global Incidence and Mortality	36
3.1.3 PET: The Most Powerful Imaging Tool in Cancer Management	36
3.1.4 Increases in Cancer Imaging Costs	37
3.1.5 New Criteria for Diagnosing Alzheimer's disease	37
3.1.6 Expanded Applications for PET in Oncology	37
3.1.6.1 PET Scanning for Prostate Cancer	38
3.1.6.2 PET/CT in Radiation Treatment Planning for Cancer Patient Treatment	38
3.1.6.3 PET in Radiation Therapy Planning	38
3.1.6.4 Imaging Protocols for PET in Radiation Therapy Planning	39
3.2 Applications of PET in Cardiology	39
3.2.1 Cost of Cardiovascular Disease	40
3.2.2 CVD: The Single Largest Killer in Adults	41
3.2.3 Prevalence of CVD in the U.S.	42
3.2.4 Economic Cost of CVD in the U.S.	43
3.2.5 PET: The Established Diagnostic Tool in Cardiology	44
3.2.6 PET and Heart Disease Diagnosis	44
3.2.7 PET/CT's Suitability in Cardiac Imaging	45
3.2.8 Need for Dedicated PET Devices for Cardiac Imaging	46
3.2.9 Impact of PET in Reducing Biopsies	46

3.2.10	Current Status of Nuclear Medicine in Cardiology	46
3.2.10.1	Current Status of Cardiac Nuclear Medicine in Asia	47
3.2.10.2	Current Status of Cardiac Nuclear Medicine in Europe	47
3.2.10.3	Current Status of Cardiac Nuclear Medicine in Latin America	48
3.2.10.4	Current Status of Cardiac Nuclear Medicine in North America	48
3.2.11	SPECT vs. PET in Cardiology	49
3.3	Application of PET in Neurology	50
3.3.1	PET's Promising Role in Diagnosing Migraines and schizophrenia	51
3.3.2	PET's key role in Parkinson's research	51
3.3.3	PET's Prediction on Surgical Outcome in Refractory Epilepsy Patients	51
3.3.4	Disease-Specific Applications of PET and PET/CT in Neurology	52
3.3.4.1	PET Imaging of Brain Tumors	52
3.3.4.2	PET and Brain Metastases	53
3.3.4.3	PET in Dementia	53
3.3.4.4	PET in Epilepsy	53
4.	PET Radioisotopes and Radiopharmaceuticals	55
4.1	Types of Radiopharmaceuticals	56
4.1.1	Diagnostic Radiopharmaceuticals	57
4.1.2	Suppliers of Radiopharmaceuticals	57
4.1.3	Radioisotopes Used in Medicine	58
4.1.4	Cyclotron Radioisotopes	59
4.1.5	FDA-Approved Radiopharmaceuticals	61
4.1.6	Some Common Radiopharmaceuticals in PET Imaging	63
4.1.6.1	Nitrogen-13 Ammonia	65
4.1.6.2	Rubidium-82	65
4.1.6.3	Oxygen-15 Water	65
4.1.6.4	Flourine-18 fluorodeoxyglucose (FDG)	65
4.1.7	Generator-Produced PET Radiopharmaceuticals	66
4.1.8	New PET Agents for Cardiology	66
4.1.8.1	New Neuronal Imaging Agents	66
5.	Market Analysis	67
5.1	Global Market for Medical Imaging Modalities	67
5.1.1	Global Medical Imaging Market Share by Modality, 2010	67
5.2	PET and PET/CT Market	68
5.2.1	Pet and PET/CT's Application Areas	69
5.2.1.1	Global Spending on Cancer	69
5.2.1.2	U.S. Spending on Cancer and Cancer Imaging	70
5.2.1.3	U.K. Spending on Cancer	71
5.2.2	Global Market for Diagnostic Imaging Equipment for Oncology	72
5.2.2.1	Improved Diagnosis and Staging by Technological Advances	72
5.2.2.2	Importance of Imaging to Cancer Treatment	73
5.2.2.3	PET/CT Market in Oncology Sector	75
5.2.2.4	Percent Share of PET/CT Utilization by Type of Cancer	76
5.2.2.5	The Lion's Share of PET/CT Imaging in Oncology	76
5.2.3	Economic Evaluation of PET and PET/CT in Oncology	77
5.2.3.1	Costs for PET and PET/CT in Oncology	77
5.2.3.2	Cost Effectiveness of PET and PET/CT in Selected Cancer Types	78
5.2.3.3	Cost Effectiveness in the diagnosis of Solitary Pulmonary Nodules	78
5.2.3.4	Cost Effectiveness in the Detection of Non-Small Lung Cancer	78
5.2.3.5	Cost Effectiveness in the Detection of Colorectal Cancer	78
5.2.3.6	Cost Effectiveness in the Detection of Head and Neck Cancers	79
5.2.3.7	Cost Effectiveness in the Detection of Malignant Lymphoma	79
5.2.3.8	Cost Effectiveness in the Detection of Pancreatic cancer	79
5.2.3.9	Cost Effectiveness in the Detection of Other Solid Neoplasms	79

5.2.4 PET/CT: Business Models	80
5.2.4.1 The Models	80
5.2.4.2 Market Forces	80
5.2.5 Rising Demand for PET	81
5.2.5.1 Changes in PET Reimbursement	81
5.2.5.2 Initial Results from the National Oncologic PET Registry (NOPR)	81
5.2.5.3 The Road toward Open Coverage for PET	82
5.2.6 Future of SPECT and PET	82
5.3 Imaging Markets in Cardiology	83
5.3.1 Nuclear Imaging of Heart	83
5.3.2 Global Utilization of Nuclear Imaging in Cardiology	84
5.3.2.1 Future of Global Nuclear Cardiology Utilization	85
5.3.2.2 Utilization of Nuclear Cardiology Procedures in Developed Countries	85
5.3.2.3 Utilization of Nuclear Cardiology Procedures in Latin America	86
5.3.2.4 Utilization of Nuclear Cardiology Procedures in Asia/Oceania	87
5.3.2.5 Utilization of Nuclear Cardiology in Africa	88
5.3.2.6 Utilization of Nuclear Cardiology and Mortality Rate	89
5.3.2.7 Cost-Effectiveness in Nuclear Cardiology	89
5.3.2.8 Epidemiology of Cardiovascular Diseases in Developing Countries	89
5.3.3 Global Opportunities for Nuclear Cardiology Products	90
5.3.3.1 Competition in Nuclear Cardiology Market	90
5.3.4 Need for Dedicated PET Imaging in Cardiology	90
5.3.5 Market for PET Imaging Systems	91
5.3.5.1 Growth Rate for PET Cameras	92
5.3.5.2 The Decline of SPECT and the Rise of PET	93
5.3.5.3 Dedicated PET vs. Hybrid PET	94
5.3.5.4 The Different Paths of SPECT/CT and PET/CT	94
5.3.6 U.S. PET Landscape	95
5.3.6.1 PET and PET/CT Studies in the U.S. for Oncology	97
5.3.6.2 PET/CT Studies in the U.S. for Cardiology	98
5.3.6.3 PET/CT Studies in the U.S. for Neurologic Studies	98
5.3.6.4 U.S. Growth Rate for PET Procedure Volume	99
5.3.7 Utilization of PET Scanners in the U.S. Finger Lakes Region	100
5.3.7.1 U.S. PET Utilization by Body Site	101
5.3.7.2 PET Utilization by Payment Type	101
5.3.7.3 U.S. PET Utilization Rates	102
5.3.7.4 U.S. Demand for SPECT, SPECT/CT, PET and PET/CT	102
5.3.8 U.S. Cardiac PET Payments	103
5.3.8.1 Opposition for Reduction	103
5.3.8.2 Breakeven Point	104
5.3.9 CMS Coverage for Cancer Patients and PET/CT Growth	104
5.3.9.1 Opportunities for the Providers of PET and PET/CT	106
5.3.10 Medicare Reimbursement for PET Procedures	107
5.3.10.1 Coding	107
5.3.10.2 Reimbursement	108
5.3.10.3 Payment for Diagnostic Radiopharmaceuticals	108
5.3.11 U.S. Market for PET	110
5.3.12 PET Landscape across Canada	110
5.3.13 PET scanning in Canada	115
5.3.13.1 Publicly Funded PET Scanning in Canada	116
5.3.13.2 Privately Funded PET Scanning in Canada	117
5.3.13.3 Utilization of PET in Ontario	117
5.3.13.4 CVD: Number One Killer in Canada	118
5.3.14 PET Landscape in Europe	118
5.3.14.1 PET Installations in Europe	119
5.3.14.2 Growth of PET/CT in the E.U. Market	119

- 5.3.14.3 PET/CT Procedures in Europe 120
- 5.3.14.4 Locations of PET Centers in Europe 121
- 5.3.14.5 PET Studies per Million Population in Europe 121
- 5.3.14.6 The Commercial Isotope Market in Europe 122
- 5.3.15 Availability of PET in U.K 123
 - 5.3.15.1 PET Units in Europe 124
 - 5.3.15.2 Cyclotron-Based Isotopes 124
 - 5.3.15.3 Nuclear Imaging Leaders in Europe 125
 - 5.3.15.4 European Market for PET/CT 126
 - 5.3.15.5 Nuclear Imaging System Market in Germany 127
 - 5.3.15.6 Nuclear Imaging Market in France 127
 - 5.3.15.7 U.K. Nuclear Imaging System Market 128
 - 5.3.15.8 Nuclear Imaging System Market in Italy 128
 - 5.3.15.9 PET Services in Europe 129
 - 5.3.15.10 PET Services in England 130
 - 5.3.15.11 Availability of PET in U.K 131
- 5.3.16 Costs of Setting up a PET Center in U.K. with a Distant Supply of Tracer 131
 - 5.3.16.1 Capital Costs 131
 - 5.3.16.2 Operating Costs 132
 - 5.3.16.3 Fixed Costs 133
 - 5.3.16.4 Variable Costs 133
 - 5.3.16.5 Costs of Setting up a PET Center in U.K. with Full Production of Tracer 133
 - 5.3.16.6 Operating Costs 134
 - 5.3.16.7 Staff Costs 136
 - 5.3.16.8 Radiotracer Production 136
 - 5.3.16.9 Fixed Costs 137
 - 5.3.16.10 Variable Costs 137
 - 5.3.16.1 Radiotracer Production 138
- 5.3.17 Nuclear Medicine Equipment and Consumables in India 138
 - 5.3.17.1 Market Trends 138
 - 5.3.17.2 Key Market Drivers 138
 - 5.3.18 Status of PET in India 139
 - 5.3.18.1 Historic Perspective 139
 - 5.3.18.2 The Isotope 139
 - 5.3.18.3 FDG Supply 139
 - 5.3.18.4 Ownership of Cyclotron 139
 - 5.3.18.5 Issues of the Cyclotron 140
 - 5.3.18.6 Regulation for Cyclotron and Isotope Supply 140
 - 5.3.18.7 Cyclotron Supply Issue 140
 - 5.3.18.8 Isotope within the End User Site 141
 - 5.3.18.9 Hardware Issues 141
 - 5.3.18.10 Indications for PET Studies in India 142
 - 5.3.18.11 Indian Nuclear Medicine Equipment Market 142
- 5.4 Nuclear Medicine 144
 - 5.4.1 Shortage of Isotopes for Medical Imaging 144
 - 5.4.2 The Supply of Medical Radioisotopes 145
 - 5.4.3 Isotopes Used in PET Imaging 145
 - 5.4.4 Isotopes Used in SPECT Imaging 146
 - 5.4.5 Rapid Growth of Radiotracers 146
 - 5.4.6 Global Market for Mo-99/Tc-99m 147
 - 5.4.6.1 Global Market for Mo-99 by Geography 147
 - 5.4.6.2 Global demand for Tc-99m 148
 - 5.4.6.3 Market Trends for Tc-99m 148
 - 5.4.6.4 Supply Uncertainties 149
 - 5.4.6.5 Pricing 149
 - 5.4.6.6 Impact of Tc-99m Pricing on Health Care Budgets 150

5.4.7 Impact of Technetium Shortage	150
5.4.7.1 Global Impact	150
5.4.7.2 Popular Medical Uses of Tc-99m	154
5.4.7.3 Market Trends for Tc-99m	155
5.4.7.4 Supply Uncertainties	155
5.4.7.5 Pricing	155
5.4.7.6 Impact of Tc-99m Pricing on Health Care Budgets	156
5.4.8 18F-fluorodeoxyglucose (FDG) Positron Emission tomography (PET)	156
5.4.9 FDG Utilization in Europe	157
5.4.10 Future of Radiopharmaceuticals	157
5.4.11 U.S. Radioisotopes Industry	158
5.4.11.1 Industry Trends and Developments	159
5.4.11.2 Market Trends for Radiopharmaceuticals and Brachytherapy	159
5.4.11.3 Supply Disruptions	161
5.4.11.4 U.S. Shipments, Consumption and Trade	161
5.4.11.5 U.S. Trade of Radioisotopes	162
5.4.11.6 U.S. Exports of Radioisotopes	162
5.4.11.7 U.S. Imports of Radioisotopes	164
6. Company Profiles	165
6.1 Actinium Pharmaceuticals, Inc.	165
6.2 Advanced Medical Isotope Corporation	165
6.2.1 AMIC's Medical Isotope Products	165
6.3 Bio-Nucleonics	166
6.3.1 Strontium Chloride Sr89	166
6.3.2 Rubigen	166
6.4 Bracco Diagnostics, Inc.	166
6.4.1 CardioGen-82	167
6.5 Covidien, PLC	167
6.5.1 Covidien's Nuclear Medicine Products	167
6.5.1.1 Duosafe	167
6.5.1.2 Indium In-111 chloride sterile solution	168
6.5.1.3 Octreoscan	168
6.5.1.4 Sodium Iodide I-131 Capsules	168
6.5.1.5 Technescan HDP	169
6.5.1.6 Thallous Chloride Tl 200	169
6.5.1.7 Ultra-Technekow Dry-Top Eluting (DTE)	169
6.5.1.8 Gallium Citrate Ga-67 Injection	170
6.5.1.9 Tc 99m Sestamibi	170
6.5.1.10 Sodium iodide I-123	170
6.5.1.11 Technescan MAG3	171
6.5.1.12 Technescan PYP	171
6.5.1.13 Ultratag RBC	171
6.6 DRAXIMAGE, Inc.	172
6.7 FluoroPharma, Inc.	172
6.7.1 FluoroPharma's technology	173
6.7.1.1 CardioPET	173
6.7.1.2 BFPET	173
6.7.1.3 VasoPET	173
6.8 GE Healthcare	174
6.8.1 GE's PET and PET-Related Products	174
6.8.1.1 CardIQ Fusion	174
6.8.1.2 CardIQ Physio	174
6.8.1.3 Dynamic VUE	175
6.8.1.4 MINItace	175
6.8.1.5 PETtace	175

- 6.8.1.6 Discovery PET/CT 600 176
- 6.8.1.7 Discovery PET/CT 690 176
- 6.8.1.8 Discovery VCT 176
- 6.8.1.9 Discovery STE 177
- 6.8.1.10 Discovery ST 177
- 6.8.1.11 Optima PET/CT 560 177
- 6.9 Lantheus Medical Imaging, Inc. 178
 - 6.9.1 Selected Products from Lantheus 178
 - 6.9.1.1 Cardiolite (Kit for Technetium Tc99m Sestamibi for Injection) 178
 - 6.9.1.2 Technetium Tc 99m Generator 178
- 6.10 MIM Software Inc. 178
 - 6.10.1 MIMfusion 179
 - 6.10.2 MIMcardiac 179
 - 6.10.3 MIMviewer 179
 - 6.10.4 MIM Storage Server 180
- 6.11 Neusoft Medical Systems Co., Ltd. 180
 - 6.11.1 Truesight PET 181
 - 6.11.2 BeyondImage Workstation (BW) 181
 - 6.11.3 CardioCARE 181
 - 6.11.4 PETCare 182
- 6.12 Nordion Inc. 182
 - 6.12.1 Nordion's Business Strategy 182
 - 6.12.2 Nordion's Medical Isotope Business Priorities 182
 - 6.12.3 Nordion's Sterilization Technologies Business Priorities 183
 - 6.12.4 Nordion's Medical Isotopes 183
- 6.13 Numa, Inc. 183
 - 6.13.1 NumaLink 183
 - 6.13.2 NumaList 184
 - 6.13.3 NumaList Plus 184
 - 6.13.4 NumaStore 185
 - 6.13.5 NumaRead 185
 - 6.13.6 NumaServer 186
 - 6.13.7 NumaManage 186
 - 6.13.8 Numa's Core Lab system 187
- 6.14 Philips Healthcare 187
 - 6.14.1 Ingenuity TF PET/CT 187
 - 6.14.2 GEMINI TF Big Bore PET/CT 188
 - 6.14.3 GEMINI TF PET/CT 188
 - 6.14.4 GEMINI TF Ready PET/CT 189
 - 6.14.5 GEMINI LXL 189
- 6.15 Positron Corporation 190
 - 6.15.1 Attrius 190
 - 6.15.2 Cardio-Assist 190
 - 6.15.3 Radiopharmaceuticals 190
 - 6.15.4 Tech-Assist 191
- 6.16 Siemens Healthcare 191
 - 6.16.1 Biograph TruePoint (16-slice PET/CT) 191
 - 6.16.2 Syngo.via 191
- 6.17 Thinking Systems Corporation 192
 - 6.17.1 MDStation 192
 - 6.17.2 MDStation for PET and PET/CT 192

INDEX OF FIGURES

Figure 2.1: Illustration of the SMART Scanner 22

Figure 2.2: Illustrations of PET, CT and Fused PET/CT Scans 22

- Figure 2.3: Collision of a Positron and Electron and the Creation of Two Resultant Gamma Rays 23
- Figure 2.4: Discharge of Two Gamma Rays at 180 Degrees 24
- Figure 2.5: A Sinogram with Coincidence Lines 24
- Figure 2.6: PET Images Viewed in Axial, Coronal and Sagittal Planes 25
- Figure 2.7: Block Diagram of PET Scanner 26
- Figure 2.8: Principles of Operation of a Combined PET/CT Scanner 30
- Figure 2.9: Two Scanners Mounted Back-to-Back for Sequential Acquisition 31
- Figure 2.10: Full Integration of a Whole-Body PET/MRI System 31
- Figure 3.1: Projection for Global Cancer Deaths, 2010-2030 36
- Figure 3.2: Projected Cost of Cardiovascular Disease, 2010-2030 41
- Figure 3.3: CVD: The Single Largest Killer in Adults 41
- Figure 3.4: Prevalence of CVD in Four of the Ethnic Groups in the U.S. 42
- Figure 3.5: Percentage Breakdown of Deaths from CVD in the U.S. 43
- Figure 3.6: Costs of Major CVD Types in the U.S. 43
- Figure 3.7: Increasing Number of Heart Failures in Europe, 2010-2020 47
- Figure 3.8: CVD in Middle Income Countries 48
- Figure 3.9: CVD in Developed Countries 49
- Figure 5.1: Global Market for Medical Imaging Equipment by Geography, 2010 67
- Figure 5.2: Global Medical Imaging Market Share by Modality, 2010 68
- Figure 5.3: Global Cancer Cases, 2009-2020 69
- Figure 5.4: U.S. Spending on Cancer, 2010-2020 70
- Figure 5.5: Spending on Cancer in U.K., 2010-2020 71
- Figure 5.6: Percent Comparison of Spending on Cancer, 2010 72
- Figure 5.7: Volume Distribution in Cancer Imaging in the U.S. 73
- Figure 5.8: Distribution of Outpatient Cancer Services in the U.S. 74
- Figure 5.9: Global Market for Diagnostic Imaging Equipment for Oncology, 2010-2017 74
- Figure 5.10: PET/CT's Share in Oncology Imaging Market, 2010-2017 75
- Figure 5.11: Percent PET/CT Imaging by Cancer Type 76
- Figure 5.12: Percent Share of Oncology, Cardiology and Neurology in PET/CT Scanning 77
- Figure 5.13: Nuclear Cardiology Procedures for 100,000 of Population per Year for Developing vs. Developed Countries 84
- Figure 5.14: Future of Nuclear Cardiology in 2014 85
- Figure 5.15: Approximate Use of Cardiac Diagnostic Testing, U.S. 86
- Figure 5.16: Utilization of Nuclear Cardiology in Developed Countries 86
- Figure 5.17: Utilization of Nuclear Cardiology in Latin America 87
- Figure 5.18: Utilization of Nuclear Cardiology Procedures in Asia/Oceania 88
- Figure 5.19: Utilization of Nuclear Cardiology in Africa 89
- Figure 5.20: Global Market for PET Services, 2010-2017 92
- Figure 5.21: Projected Market Share of PET and SPECT in 2020 93
- Figure 5.22: Growth Rate for SPECT and PET, 2011-2014 93
- Figure 5.23: Number of Cameras: SPECT Switching to PET, 2011-2014 94
- Figure 5.24: Top Ten Body Sites of Cancer for Men in the U.S. 96
- Figure 5.25: Top Ten Body Sites of Cancer in U.S. Women 96
- Figure 5.26: U.S. PET and PET/CT Patient Studies in Oncology, 2001-2008 97
- Figure 5.27: U.S. PET and PET/CT Patient Studies in Cardiology, 2001-2008 98
- Figure 5.28: U.S. PET and PET/CT Patient Studies in Neurology, 2001-2008 99
- Figure 5.29: PET-Only Sites/Studies vs. PET/CT Sites/Studies 99
- Figure 5.30: Trends in PET Procedure Volume in Finger Lakes Region, 2003-2009 100
- Figure 5.31: U.S. PET Utilization by Body Site, 2009 101
- Figure 5.32: U.S. PET Utilization Rate, 2003-2009 102
- Figure 5.33: Approximate U.S. Sales of SPECT & SPECT/CT and PET & PET/CT, 2005-2009 103
- Figure 5.34: Cardiac PET HOPPS payments, 2008-2011 104
- Figure 5.35: U.S. Market for PET, 2010-2017 110
- Figure 5.36: Percent Self-Reported Heart Disease By Age Group 118
- Figure 5.37: Installed Units of PET in E.U., 2002-2013 119
- Figure 5.38: Installed Units of PET/CT in E.U., 2002-2013 120

- Figure 5.39: Growth of PET and PET/CT Examinations in E.U., 2002-2013 120
- Figure 5.40: Location of PET Centers in Europe 121
- Figure 5.42: PET Studies per Million Populations in Europe 122
- Figure 5.41: Evolution of Cyclotron in Europe 123
- Figure 5.43: Location of PET Cameras in Europe 124
- Figure 5.44: Growth of Cyclotron Units in Europe, 2000-2010 125
- Figure 5.45: European Nuclear Imaging Market Share by Geography, 2010 125
- Figure 5.46: European Market for PET/CT, 2010-2017 126
- Figure 5.47: Nuclear Imaging Market in Germany, 2010-2017 127
- Figure 5.48: Nuclear Imaging System Market in France, 2010-2017 127
- Figure 5.49: Nuclear Imaging System Market in U.K., 2010-2017 128
- Figure 5.50: Nuclear Imaging System Market in Italy, 2010-2017 128
- Figure 5.51: Number of Installed Bases in Nuclear Medicine in India 142
- Figure 5.52: Nuclear Medicine Equipment Market in India 143
- Figure 5.53: Indian Nuclear Medicine Equipment Market by Application 143
- Figure 5.54: Global Demand Trend for Mo-99/Tc-99m 147
- Figure 5.55: Global Market for Mo-99 by Geography/Country, 2009 148
- Figure 5.56: Global Demand for Tc-99m (48 Million Doses/Year), 2009 148
- Figure 5.57: Composition of Nuclear Medicine Procedures Utilizing Tc-99m 152
- Figure 5.58: Global Demand for Mo-99 and Tc-99 153
- Figure 5.59: U.S. FDG Sales, 2010-2017 156
- Figure 5.60: U.S. Sales of Diagnostic Radiopharmaceuticals, 2007-2014 159
- Figure 5.61: U.S. PET Procedure Volume Increase, 2007-2015 160
- Figure 5.62: U.S. Sales of Fluorodeoxyglucose (FDG), 2007-2015 160
- Figure 5.63: U.S. Export Share in Radioisotopes by Major Markets, 2007 162
- Figure App. 2.1: Number of Global Nuclear Medicine Procedures Using for $^{99m}\text{Tc}/^{99}\text{Mo}$, 1990-2020 199
- Figure App. 2.2: Growth of ^{99}Mo Requirements, 1990-2020 199
- Figure App. 2.7: Quantity of ^{99}Mo Delivered to End-Users by Geography, 2007 200
- Figure App. 2.8: Regional Shares of Reactor Production of ^{99}Mo , 2007 200
- Figure App. 2.9: Regional Shares of Reactor Production and Requirements of ^{99}Mo , 2007 201
- Figure App. 2.10: Regional Shares of Reactor Production and Requirements of ^{99}Mo , 2007 202
- Figure App. 5.1: Types of Nuclear Medicine Procedures that Can be Done Using Tc-99m 211
- Figure App. 5.2: The basic linear supply chain for Tc-99m 212
- Figure App. 5.3: North American Supply Chain for Tc-99m 213
- Figure App. 5.4: Global Supply Chains for Tc-99m 214
- Figure App. 5.5: Global Market Share by Reactor for Tc-99m 214
- Figure App. 6.1: Growth in Allowed Services and Allowed Charges for Advanced Imaging Paid Under the MPFS, 1995 to 2005 217
- Figure App. 6.2: Percentage of Total Growth in Allowed Services by Imaging Modality, 1995 to 2005 218
- Figure App. 6.3: Percentage of Total Growth in Allowed Charges by Imaging Modality, 1995 to 2005 218
- Figure App. 6.4: Growth in Advanced Imaging Utilization Rates, 1995 to 2005 219

INDEX OF TABLES

- Table 2.1: Comparison of PET with Other Imaging Modalities 27
- Table 2.3: Average Adult PET and PET/CT Scan Times 33
- Table 2.4: Applications of PET in Oncology 35
- Table 3.1: Applications of PET in Cardiology 40
- Table 3.2: Characteristics of SPECT vs. PET in Cardiac Imaging 45
- Table 3.3: List of Common PET Tracers Used in the Evaluation of Neurological Disorders 52
- Table 4.1: Common PET Radioisotopes 55
- Table 4.2: Examples of PET Radiopharmaceuticals 55
- Table 4.3: Estimated Radiation Dose with Intravenous Administration of FDG in a 70-kg Patient 56
- Table 4.4: PET Radiopharmaceuticals: Their Applications, Mechanisms of Uptake and Localizations 59
- Table 4.5: FDA-Approved Radiopharmaceuticals as of August 3, 2010 61
- Table 5.1: U.S. PET Locations and Exams 97

Table 5.2: Utilization by Payment Type in Finger Lake Region, 2009	101
Table 5.3: Effect of Coverage Changes on Oncologic Uses of FDG PET	105
Table 5.4: Volume Outlook for Outpatient Imaging, 2005-2015	107
Table 5.5: Medicare Reimbursement for PET Procedures	109
Table 5.6: Publicly Funded PET Scanners in Canada, 2009	111
Table 5.7: Funding for PET Scans (Period prior to October 1, 2009)	112
Table 5.8: Alberta Indications	113
Table 5.9: Estimated Ontario New Cancer Cases, 2009	114
Table 5.10: Publicly Funded PET Scanners in Ontario 2009	115
Table 5.11: Approved International Indications for Clinical Use of 18F-FDG	116
Table 5.12: Availability of Publicly Funded Clinical PET Scanning in Canada	116
Table 5.13: European PET, PET/CT, PET/NM Installations	119
Table 5.14: Typical Radiation Doses	123
Table 5.15: PET Scanning Facilities in Europe	129
Table 5.16: PET Scanning Facilities in England	130
Table 5.17: Typical Radiation Doses	131
Table 5.18: Capital Costs for a PET Center with a Distant Supply of Tracer	132
Table 5.19: Staff Costs per Annum for Imaging with a Distant Supply of Tracer	132
Table 5.20: Fixed Costs per Annum for Imaging with a Distant Supply of Tracer	133
Table 5.21: Variable Costs per Annum for Imaging with a Distant Supply of Tracer	133
Table 5.22: Total Capital Scanning Costs for Imaging and Radiotracer Production Facility	134
Table 5.23: Capital Costs for Full Production of Radiotracer within an Imaging and Full Production of Tracer Facility	134
Table 5.24: Staff Costs per Annum for an Imaging and Full Production of Tracer Facility	136
Table 5.25: Staff Costs for the Cyclotron and Radiochemistry Within an Imaging and Full Production of Tracer Unit	137
Table 5.26: Fixed Radiotracer Production Costs	137
Table 5.27: Variable Scanning Costs	137
Table 5.28: Radiotracer Production Variable Costs	138
Table 5.29: Medical Cyclotrons in India	140
Table 5.30: PET/CT Scanner Profile in India	141
Table 5.31: PET/CT Scanners by Number of Slices in India	141
Table 5.32: Major current 99Mo producing reactors	145
Table 5.33: Characteristics of Positron Emitting Tracers Used in PET Perfusion Imaging	146
Table 5.34: Worldwide Production Capacity of 99Mo, 2009	151
Table 5.35: Small Scale Production of 99Mo, 2010	151
Table 5.36: Nuclear Medicine Procedures that Use Tc-99m	154
Table 5.37: Radiopharmaceuticals of Clinical Use in Europe	157
Table 5.38: Useful Radionuclides for Molecular Imaging	158
Table 5.39: U.S. Shipments, Consumption and Trade of Radioisotopes	161
Table 5.40: U.S. Exports, Imports and Trade Balance by Selected Countries, 2003-2007	163
Table 5.41: U.S. Imports of Radioisotopes for Consumption, 2003-2007	164
Table 6.1: Actinium's Product Pipeline	165
Table App. 1.1: Global Reactor Landscape	194
Table App. 1.2: Global Share of Nuclear Medicine by Reactor, 2009	195
Table App. 2.1: Radionuclides for Which Supply is Believed to be in Jeopardy in 2010-2020	198
Table App. 3.1: Imaging Properties of PET Crystals	203
Table App. 3.2: Average adult PET and PET/CT Scan Times	204
Table App. 3.3: Common PET Radioisotopes	205
Table App.3.4: Examples of PET Radiopharmaceuticals	205
Table App. 4.1: Research Reactors Producing Radioisotopes	207
Table App. 4.2: Estimated Worldwide Value of Radioisotope Production	210
Table App. 6.1: Ten Most Frequently Billed Advanced Imaging Procedure Codes, 2005	220
Table App. 6.2: Growth in Allowed Charges for Imaging Under the MPFS by Year, 1995-2005	220
Table App. 6.3: CT Services Billed Under the MPFS by Provider Specialty, 1995-2005	220
Table App. 6.4: PET Services Billed Under the MPFS by Provider Specialty, 1995-2005	222

1. Overview

The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment. Continuous improvements in technology are resulting in a growing number of new imaging tests that combine high levels of accuracy with rapid, easy-to-use product formats. Part of that medical imaging improvement is coming from positron emission tomography (PET). PET is a scanning technique used in combination with small amounts of radio-labeled compounds to visualize the anatomy and function of the brain.

The purpose of this TriMark Publications report is to describe the specific market segment of the diagnostics medical imaging market called PET scanning. This sector includes all of the generally accepted imaging activities that are currently used in PET, including equipment for PET, PET/CT, SPECT and the use of radiopharmaceuticals for imaging. It examines these clinical measurement devices and their reagents and supplies as used in hospitals and clinics. It also reviews associated clinical market segments in which PET scanning has taken a prominent role including cancer treatment, cardiology, and neurology imaging markets.

PET scanning is the fastest growing medical imaging modality in the U.S. as well as the European and other developing regions of the world. Its principal role has been in oncology, where it has an increasing role in diagnosis, the monitoring of treatment or the progression of disease and in the staging of patients for radiation therapy. Most of the oncology PET procedures are now reasonably reimbursed under Medicare and by insurance companies. Research has proved the effectiveness of diagnostic applications in cardiology and neurology and reimbursement as clinical procedure is expected soon.

Growth of the PET market from its clinical beginnings in the early 1990s has been rather impressive, but it has been hindered by the non-availability of the radiopharmaceutical required for imaging. As the physical half life of ^{18}F (FDG) is short (110 minutes) and as it has to be generated using a particle accelerator (*e.g.*, cyclotron), each PET scanner is required to be in close proximity to a commercial PET radiopharmaceutical manufacturing facility that costs \$██████ to \$██████ to construct. Consequently, clinical PET is usually available only in big cities where a radiopharmaceutical manufacturing facility can offer its radioisotope to a minimum of ██████ or ██████ PET scanners. Commercial PET radiopharmaceutical manufacturing, and to some extent PET scanning itself is not a profitable business in a geographical region with an accessible population of less than ██████.

The recent PET scanners available in the market are made up of a large number of detectors arranged on numerous rings and are able to identify pairs of 511 KeV photons emitted at 180° to each other which are formed following the annihilation of a positron when it meets an electron. In a PET/CT hybrid scanner, the PET and CT tomographs are placed in a single gantry with a single patient bed and workstation. PET/CT scanners can also be used either as a dedicated PET scanner or as a dedicated CT scanner. On reconstruction, both the PET images and the CT images can be viewed side by side and overlaid. PET/CT brings together functional (PET) and structural (CT) information into a single scanning session, enhancing lesion localization and interpretation accuracy. Presently, PET/CT is the most advanced technique of metabolic imaging and the most efficient tool for tumor staging in the pretreatment, post-treatment and follow-up phases. Technological improvements of PET/CT scanners are anticipated in the near future with an improvement in the efficiency of detector crystals, the spatial resolution and a reduction in acquisition times of the emission images.

1.1 Scope of This Report

The main objectives of this report are to:

- Identify viable technology drivers through a comprehensive look at various platform technologies for PET.
- Obtain a complete understanding of the use of PET—predictive, screening, prognostic, diagnostic and monitoring—from its basic principles to its applications.

- Discover feasible market opportunities by identification of high-growth applications in different imaging areas, with a focus on the biggest and expanding markets for PET.
- Focus on global industry development of PET through an in-depth analysis of the major world markets for medical imaging, including forecasts for growth.
- Establish the essentials of the PET imaging market including definitions, processes and trends.

Market figures regarding the current value of the medical imaging market are taken from the most recently available data of the global medical products industry. This report covers the following categories of medical imaging:

- PET.
- PET/CT (computed tomography) combinations.
- SPECT (single-photon emission computed tomography).
- Radiopharmaceutical imaging.

Analysis of PET scanning includes the use of charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research into the medical imaging arena provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status, and research and development trends, is provided throughout the report. The study will:

- Assess the PET market drivers and bottlenecks, from the perspective of the medical and scientific communities.
- Discuss the potential benefits of the PET market for various sectors of the medical and scientific community.
- Establish the current total market size and future growth of the PET market and analyze the current size and growth of various segments.
- Provide current and forecasted market shares by company.
- Discuss profit/business opportunities by imaging segment.
- Provide strategic recommendations for near-term business opportunities.
- Assess current commercial uses of the PET technology platforms.
- Review the PET business models.

PET products consist of hardware, software and supplies used to create, view and manage visual images of non-visible organs of the human body for purposes of research, diagnosis and guidance of non-invasive surgery. This report will focus on end-user markets including hospitals, research facilities, freestanding clinics and equipment-leasing companies. In the past few years, several multimodal products have been developed in an attempt to combine the advantages of structural and functional imaging. Multimodal combinations discussed in this study include:

- CT/SPECT units.
- CT/PET units.

The emphasis in this analysis is on those companies that are actively developing and marketing PET technologies. The reader should consult other TriMark reports at <http://www.trimarkpublications.com> for a detailed discussion of the other important individual market segments that are related to the medical imaging markets, such as X-ray and radiography, mammography, magnetic resonance imaging (MRI), ultrasound, gamma camera market, computed tomography (CT) scans, and picture archiving and communication systems (PACS).

This report concentrates on the medical imaging market segment in important worldwide markets such as the U.S. and Europe. It focuses primarily on the hospital market segment, and, separately, on a description of the instruments, reagents and supplies marketed by major companies in the PET segment. The analysis discusses the market size, growth rates and market components for instruments and reagents, controls and consumables used in PET, with mention of contrast media and biopharmaceuticals used to enhance imaging

resolution. This study reviews the market for medical imaging in the clinical and research hospital market. It defines the dollar volume of sales of the market, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments.

The report discusses activity and trends in the PET market and goes on to discuss in detail the trends that have stimulated this market. This analysis also comments on the patterns of information processing in the PET market. It surveys all of the companies known to be marketing, manufacturing or developing PET equipment in the U.S. and worldwide. Leading companies are discussed in depth with a section on the history of the company, the product line, business and marketing analysis, and a subjective commentary of the position of the company in its market.

1.2 Methodology

The author of this report is a Ph.D. in biochemistry from the University of Minnesota with many decades of experience in science writing and as a medical industry analyst. He has been a senior director of several large regional and national healthcare laboratories. The editor is a retired college professor with three decades of experience in teaching biochemistry, biotechnology and pharmacology. Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additionally, important data sources include American Hospital Association (AHA), American College of Radiology (ACR), World Health Organization (WHO), National Cancer Institute, American Cancer Society (ACS), International Atomic Energy Agency (IAEA), *Journal of Nuclear Medicine and Technology* (JNMT), *Biomedical Imaging and Intervention Journal*, International Academy of Cardiovascular Sciences and Medical Imaging & Technology Alliance (MITA). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that TriMark believes to be reliable, but do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects and Sector Snapshots that we publish annually. We extract relevant data and analytics from TriMark's research in the past three years as part of this data collection. We also extract qualified data feeds from e-questionnaire responses and primary research responses for this compilation.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government affiliated trade releases, and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations. The report conclusions are verified through intensive interviewing of the top-ranking companies in the industry.

TriMark Publications Report Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report in TriMark Publications includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly-available data and proprietary databases.
- Formulating a study outline with the assigned writer, including important items, as follows:
 - Market and product segment grouping, and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
- Identifying the key technology and market trends that drive or affect these markets.
- Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of expert panel partners.

1.3 Executive Summary

There will be a steady increase in demand for PET services as resolution improves and PET is combined with other modalities like CT. The medical imaging segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the computer and digital information technology segment. Continuous improvements in technology are resulting in a growing number of new imaging tests that combine high levels of accuracy with rapid, easy-to-use product formats. Another major driver is the high interest of individual older baby boom patients and general healthcare consumers to monitor health status. Competition in the development and marketing of PET products is intense, and these diagnostic technologies have been subject to rapid change. We estimate that the competitive factors in the PET market include resolution, price and product performance as well as the distribution, advertising, promotion and brand-name recognition of the marketer. There are relatively few large, dominant global players selling PET equipment; these are matched by many small companies with a few or one product aiming at niche markets. A relative handful of firms led by GE Medical Systems, Philips Medical Systems International BV and Siemens Medical Solutions dominate the world medical imaging equipment market. However, due to the broad technology underlying the various forms of medical imaging, there are many other companies that perform very well in this sector, such as:

- Carestream Health, Inc. (U.S.).
- Fonar Corporation (U.S.).
- Hitachi Medical Systems America, Inc. (U.S.).
- Hologic, Inc. (U.S.).
- Medison America, Inc. (U.S.).
- The Esaote Group (Italy).
- TomTec Imaging Systems GmbH (Germany).
- Toshiba America Medical Systems (U.S.).

With the development of combined PET/CT devices, the market for PET scanners has decreased as it has increased for PET/CT scanners. The number of commercial facilities providing FDG has increased and the number of doses of FDG provided per facility has increased. PET/CT scanners continue to improve, and provide better quality images in shorter acquisition times. The PET/CT scanners have resulted in the capability of doing more patients per day than could be done by PET alone devices. Because of the reimbursement and the rapid expansion of clinical indications, the PET market grew rapidly. Most metropolitan areas in the U.S. have ready access to FDG and back-up production sites are generally available to provide FDG if a primary site has a problem.

PET became a [REDACTED] dollar industry as early as in [REDACTED]. The current new sales are [REDACTED]% PET/CT, with very few PET alone devices being sold. The reasons that PET only systems were being bought in recent years are the following: software image fusion can provide registration of the PET with CT or MRI images; CT adds from \$[REDACTED] to \$[REDACTED] to the cost of the device. The reasons that combined PET/CT devices are being bought are the following: noise-free attenuation correction; short duration transmission scans; shorter duration scans and faster patient throughput; anatomic lesion localization; potential added revenue from CT; competition factor (having the newest and best); adjunct to already established CT service (additional CT access); and improved registration, not only for diagnostic purposes but also for use with radiation oncology for radiation therapy planning and intensity-modulated radiation therapy.

The efficacy of dedicated PET and PET/CT scanners depends on the type of scintillation crystal employed in the detector and the crystal oxyorthosilicates was the clear winner in [REDACTED]. For Siemens, over half of its orders in 2010 were for scanners with the LSO (lutetium oxyorthosilicate) crystal. For Philips Medical Systems, its proprietary GSO (gadolinium oxyorthosilicate) offers improved throughput and image quality by allowing more counts than BGO (bismuth germanate) and sodium iodide, the older, established crystal technologies. Philips and Siemens provide PET scanners with BGO scintillators as lower cost recourse to their premium systems. Philips' Allegro and Siemens' Ecat Accel are built from fast scintillators, as the wave of the future. These manufacturers, along with CTI Molecular Imaging, see a chance to gain not only revenue but a marketing edge over rival GE Medical Systems. That edge is achievable for both dedicated PET and PET/CT scanners, because GE's PET systems use only BGO. The collaboration between CTI and Siemens, called CTI PET Systems (CPS) provides both companies with LSO-based detectors. CTI announced booming sales in [REDACTED], mostly due to the increasing popularity of LSO. Siemens' sales outperforms those of CTI mainly because of Siemens' name recognition and its well-established distribution channels in radiology. Speed is responsible for the growing popularity of LSO and GSO. These two crystals, after emitting a flash of light, become ready to emit another flash in about [REDACTED] nanoseconds. BGO needs a period five times as long. The time required for an imaging is thus much shorter for GSO- and LSO-based systems than those built around BGO.

The global market for PET/CT is on the upswing as PET's clinical use continues to attract global recognition. The hybrid PET/CT is increasing PET's functionality with radiologists, enabling the images easier to interpret in a familiar format. Growth in number of procedures is also increasing mainly due to approvals of indications such as breast imaging and increased utilization of PET in detecting lung cancer, colon cancer, lymphoma and melanoma. The major application of PET is only in oncology and yet, utility in cardiology applications is expanding in diagnosing myocardial viability and follow-up to equivocal SPECT studies. Procedure volume is also being propelled by the availability of PET/CT with multislice configurations appropriate for cardiac imaging. The quick adoption of PET/CT has increased the financial pressure on PET service providers and as a result they are trying to offset the high capital investment with billable procedures. This has generated unprecedented competition for PET referrals. PET/CT has been accepted very quickly both in the U.S. and internationally. Vendors have geared up for higher shipments in the U.S., anticipating sales growth. The cost of PET scanners has declined to an average price of \$[REDACTED] to \$[REDACTED] per scanner. TriMark's research reveals that the global sales of PET systems will increase from about \$[REDACTED] in [REDACTED] to \$[REDACTED] by [REDACTED]. According to the market projection by [REDACTED], the number of PET cameras globally will increase from a mere [REDACTED] in [REDACTED] to [REDACTED] in [REDACTED]. TriMark estimates that the U.S. market for PET systems was worth about \$[REDACTED] in [REDACTED] and it is anticipated to reach \$[REDACTED] in [REDACTED]. TriMark's research also reveals that, in the U.S. there were approximately [REDACTED] PET units and this number is likely to increase to [REDACTED] units in [REDACTED].